A Cancer Detection Test Fails in Major Study The New York TimesGrail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint Fierce BiotechGrail shares plummet after UK study raises doubts over cancer test's prospects ReutersGrail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Business Wire
